Home
About Us
Guidelines
Popular Articles
Submission Service
RSS FEEDS
Contact Us
Submit Article

Mark Ramirez's Articles

Display Category|Title|Newest|Oldest
  • Congress Poised to Hand Over Tobacco Oversight to FDA
    The US Congress is on the verge of passing a bill that will give the US Food and Tobacco Agency the authority to regulate tobacco. Expert analysis on whether is still back and forth on whether the bill will affect the actual use of tobacco.
  • Oxycotin Ruled Addictive, Drug Makers Fined for Misleading Public
    Last Friday, U.S. District Judge James Jones ordered Purdue Pharma L.P., the maker of OxyContin, to pay $634.5 million in fines for misleading the public about the addictiveness of the painkiller.
  • Another New Study Rips Avandia
    According to analysis published by the the Cochrane Library, “A new meta-analysis of 18 studies finds that Glaxo’s diabetes pill doesn’t “positively influence” the health of diabetics, reduce death, improve quality of life, but does contribute to weight gain, swelling, heart risks and broken bones.
  • Avandia Related Heart Attacks Surge
    According to reports by the Associated Press, Avandia side effects reports have tripled in the month after the report that the blockbuster drug used to treat diabetes drastically raised users risk of heart attack.
  • Uninsured Americans Raise Medicare Expenditures
    A new study shows that Americans who were not insured before the age of 65 and gained access to Medicare cost the system exponentially more money than those who were previously insured with prior health insurance.
  • FDA OK’s New Alzheimer’s Patch
    On July 9th, the Swiss Drug Maker Novartis received approval from the American Food and Drug Administration to begin selling its Exelon skin patch used to treat Alzheimer’s.
  • FDA OK’s New Alzheimer’s Patch
    On July 9th, the Swiss Drug Maker Novartis received approval from the American Food and Drug Administration to begin selling its Exelon skin patch used to treat Alzheimer’s.
  • Study Suggests Vioxx Risks were Covered Up
    Results from a new study show that increased heart risks that were produced by Merck's Vioxx began immediately, and not after 18 months as the company has stated. The study could potentially strike a whole in Merck’s defense, who is still involved in ongoing litigation.
  • All Diets are Created Equal
    The results of a new study examining the effectiveness of diets is out, and point out that most all diets help dieters lose weight the same. The study led by Dr. Michael Dansinger of the Tufts-New England Medical Center in Boston found that the effect of dietary counseling for weight loss on average, resulted in weight loss of around 6 percent of patients initial body weight after one year, compared with people not involved in formal weight loss programs.
  • Merck to Cut Spending by 9% by the End of the Year
    Merck will downsize its spending on promotions and sales force by 9% the end of the year. Sources at Merck have stated that spending will include job losses although final figures had not been agreed upon.
  • FDA’s New Survey Says Trust in FDA Renewing
    A new poll says that public trust in the FDA is beginning to rebound after a steady decline the last 2 years, but there is still much more work to do.
  • New Weight Loss Drug Keeps Users Looking For the Toilet
    Alli, the first FDA approved OTC diet aid has hit shelves, and is guaranteed to be a big hit. The new medication promises to enhance weight loss 50% more than dieting alone by preventing the body from digesting the fat on ingested food. The only problem is the leakage.
  • New Options for Rheumatoid Arthritis
    A new era for rheumatoid arthritis is beginning to unfold, leading the charge is several new drugs which are giving arthritis sufferers new options that many have never enjoyed.
  • Avandia Increases Risk of Heart Attack
    The widely prescribed diabetes drug Avandia was found in a recent study to increase the risk of heart attack in patients by 43%. The findings of the recent study will be published in June 14 issue of The New England Journal of Medicine.
  • FDA Pushes to Broaden Warnings On Anti-Depressants
    The FDA is urging that a new warning be placed on the labels of all anti-depressants warning of an increased risk of suicidal thoughts and behavior. The current warning label warns of a increase of suicidal thoughts and behavior in children 18 and younger, but the FDA says that the warning should be expanded to also include young adults from 18-24 years old.

[1] [2]

Member Login

Recent Articles

RSS Feeds by Category
  Site Links We Support:
  Home
About Us
Contact Us
RSS Feeds
Privacy Policy
Terms of Service
Link Partners
 
 


**scoop**

Powered by Article Dashboard